<DOC>
	<DOCNO>NCT00931944</DOCNO>
	<brief_summary>This open-label , multi-center study design extend evaluation safety , tolerability , clinical effect oral administration KNS-760704 patient ALS .</brief_summary>
	<brief_title>Open-Label , Safety Tolerability Extension Study KNS-760704 Amyotrophic Lateral Sclerosis ( ALS ) ( CL211 )</brief_title>
	<detailed_description>Patients complete Part 2 Week 28 visit study KNS-760704-CL201 patient ALS actively receive RTPB [ ( 6R ) -4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydro-chloride monohydrate ] Research IND # 60,948 may eligible participate study . Eligible patient receive 1 tablet KNS-760704 150 mg every 12 hour ( Q12H ) ( 300 mg total daily dose ) 180 week .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Patient provide sign informed consent trial commencement studyrelated procedure 2 . Patient actively participate Knopp Protocol KNS760704CL201 complete Part 2 Week 28 visit study patient actively receive RTPB Research IND # 60,948 1 . Patient participate Knopp Protocol KNS760704CL201 patient receive RTPB Research IND # 60,948 . 2 . Patient discontinue KNS760704CL201 reason enrollment study ( applies patient enrol KNS760704CL201 ) 3 . Patient take RTPB Research IND # 60,948 prior April 30 , 2009 ( applies patient enrol Research IND # 60,948 )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>ALS</keyword>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Lou Gehrig</keyword>
	<keyword>Lou Gehrig 's</keyword>
	<keyword>Lou Gehrig 's disease</keyword>
	<keyword>Motor Neuron Disease</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>KNS-760704</keyword>
	<keyword>RTPB</keyword>
</DOC>